Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

Stock Performance - Astrazeneca's stock ended at $69 45, marking a +1 97% increase from the previous day's close [1] - The stock outperformed the S&P 500, which gained 0 74%, while the Dow dropped 0 01% and the Nasdaq increased by 1 68% [1] - Over the past month, Astrazeneca's shares gained 0 78%, while the Medical sector lost 4 72% and the S&P 500 gained 0 8% [1] Earnings and Revenue Expectations - Astrazeneca is expected to report Q1 2024 EPS of $0 95, down 1 04% from the prior-year quarter [1] - Revenue for the quarter is expected to be $12 billion, a 10 27% increase compared to the year-ago quarter [1] - For the entire fiscal year, consensus estimates project earnings of $4 02 per share and revenue of $51 01 billion, representing year-over-year changes of +10 74% and +11 34%, respectively [2] Analyst Estimates and Valuation - Recent changes to analyst estimates reflect optimism about Astrazeneca's business and profitability [2] - The Zacks Consensus EPS estimate has moved 0 08% lower over the past month, and Astrazeneca currently holds a Zacks Rank of 3 (Hold) [3] - Astrazeneca is trading at a Forward P/E ratio of 16 95, a premium compared to its industry's average of 14 1 [3] - The company's PEG ratio is 1 25, lower than the industry average of 1 71 [3] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 223, placing it in the bottom 12% of all industries [4] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [4]